Targeting STAT3 Enzyme for Cancer Treatment

被引：0

作者：

Arun, Sowmiya ^{[1
]}

Patel, Praveen Kumar ^{[1
]}

Lakshmanan, Kaviarasan ^{[2
]}

Rajangopal, Kalirajan ^{[1
]}

Swaminathan, Gomathi ^{[1
]}

Byran, Gowramma ^{[1
]}

机构：

[1] JSS Acad Higher Educ & Res, Dept Pharmaceut Chem, JSS Coll Pharm, Nilgiris 643001, Tamil Nadu, India

[2] Satyabhama Inst Sci & Technol, Sch Pharm, Dept Pharmaceut Chem, Chennai, Tamil Nadu, India

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2024年 / 24卷 / 13期

关键词：

STAT3; inhibitors; SH-2; domain; proliferation; phosphorylation; hematological malignancies; tyrosine residue; NF-KAPPA-B; SIGNAL TRANSDUCER; TRANSCRIPTION; 3; KEY REGULATOR; EXPRESSION; ACTIVATOR; COMMUNICATION; SUPPRESSOR; APOPTOSIS; REVEALS;

D O I：

10.2174/0113895575254012231024062619

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A category of cytoplasmic transcription factors called STATs mediates intracellular signaling, which is frequently generated at receptors on cell surfaces and subsequently sent to the nucleus. STAT3 is a member of a responsible for a variety of human tumor forms, including lymphomas, hematological malignancies, leukemias, multiple myeloma and several solid tumor types. Numerous investigations have demonstrated constitutive STAT3 activation lead to cancer development such as breast, head and neck, lung, colorectal, ovarian, gastric, hepatocellular, and prostate cancers. It's possible to get a hold of the book here. Tumor cells undergo apoptosis when STAT3 activation is suppressed. This review highlights the STAT3 activation and inhibition which can be used for further studies.

引用

页码：1252 / 1261

页数：10

共 50 条

[31] A New Scalpel for the Treatment of Pancreatic Cancer: Targeting Stromal-Derived STAT3 Signaling
Cowan, Robert W.
Maitra, Anirban
Rhim, Andrew D.
GASTROENTEROLOGY, 2015, 149 (07) : 1685 - 1688
[32] Targeting STAT3 in the Vascular Endothelium
Moss, B. J.
Mckenna, N.
Ochsner, S.
Coarfa, C.
Kanchi, R.
Castillo, R. E. Cardenas
Poli, F.
Garcia, J. D. Cala
Agarwal, S. K.
Rosas, I. O.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[33] Targeting STAT3 in castration-resistant prostate cancer: Galiellalactone as a direct inhibitor of STAT3 in prostate cancer cells.
Hellsten, Rebecka
Don-Doncow, Nicholas
Escobar, Zilma
Johansson, Martin Hans
Kjellstrom, Sven
Garcia, Victor
Munoz, Eduardo
Sterner, Olov
Bjartell, Anders
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[34] Novel STAT3 inhibitor in the Treatment of Breast Cancer
Senthil, M.
Xing, Q.
Yin, J.
Buettner, R.
Horne, D.
Jove, R.
Yim, J.
ANNALS OF SURGICAL ONCOLOGY, 2010, 17 : S50 - S50
[35] Challenges Associated With Therapeutic Targeting Of Stat3 For The Treatment Of Pulmonary Hypertension
El Kasmi, K. C.
Riddle, S. R.
Pugliese, S.
Frid, M. G.
Li, M.
Anderson, A.
Sokol, R.
Stenmark, K. R.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
[36] Targeting the JAK2/STAT3 pathway in ovarian cancer
Gritsina, Galina
Xiao, Fang
O'Brien, Shane W.
Maglaty, Marisa A.
Xu, Ren-Huan
Sigal, Luis J.
Litwin, Samuel
Connolly, Denise C.
CANCER RESEARCH, 2014, 74 (19)
[37] Targeting STAT3 as a therapeutic strategy to sensitize colorectal cancer to chemoradiotherapy
Grade, M.
Spitzner, M.
Roesler, B.
Bielfeld, C.
Gaedcke, J.
Wolff, H.
Beissbarth, T.
Wienands, J.
Ghadimi, M.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 99 - 99
[38] MULTIFUNCTIONAL DNA NANOSTRUCTURES FOR SELECTIVE TARGETING OF STAT3 IN COLORECTAL CANCER
Pacifico, T.
Unida, V
Tomassini, L.
Laudisi, F.
Ortenzi, A.
Colantoni, A.
Monteleone, G.
Biocca, S.
Stolfi, C.
DIGESTIVE AND LIVER DISEASE, 2024, 56 : S141 - S141
[39] Targeting the STAT3 oncogenic pathway: Cancer immunotherapy and drug repurposing
Dong, Yushan
Chen, Jingyu
Chen, Yuhan
Liu, Songjiang
BIOMEDICINE & PHARMACOTHERAPY, 2023, 167
[40] Targeting constitutively-activated STAT3 in hypoxic ovarian cancer
McCann, Georgia A.
ElNaggar, Adam
Naidu, Shan
Rath, Kellie S.
Tierney, Brent J.
Suarez, Adrian
Cohn, David E.
Selvendiran, Karuppaiyah
CLINICAL CANCER RESEARCH, 2015, 21

← 1 2 3 4 5 →